Appendicitis Market Trends

Growth Drivers

• Surgical advancements coupled with aging populations: The rise of laparoscopic appendectomy and other minimally invasive procedures has made appendicitis treatment more effective, safer, and less risky. For instance, in 2021 as per the European Commission laparoscopic appendectomy rates were over 90% in France and Denmark. These techniques offer shorter recovery times and fewer complications, encouraging timely medical care. Additionally, the global increase in the elderly population with 1 in 6 people in the world aged 60 years or over by 2030 per WHO in Oct 2024, is contributing to a rise in health complications, including appendicitis. Older individuals are more prone to complications from untreated appendicitis, further driving the demand for timely and effective treatment. Thus, propelling the appendicitis market.

Challenge

• High Cost of Treatment: The cost of appendicitis treatment, particularly for surgical procedures like laparoscopic appendectomy, can be a significant burden, particularly in low-income regions. The expenses associated with diagnostic tests, hospital stays, anesthesia, and post-surgery care often lead to financial strain for patients and their families. This financial barrier can limit access to timely medical intervention, particularly in areas with limited healthcare infrastructure, exacerbating the risk of complications and affecting overall treatment outcomes. Thus, restricting the appendicitis market.
• Rising Antibiotic Resistance: Continuous rise in resistance towards antibiotics has become challenging for the treatment of appendicitis with antibiotics alone in cases where surgery is not immediately necessary. Resistant infections complicate the management of appendicitis, making it harder to control infections effectively without surgical intervention. Additionally, the rise in antibiotic resistance can complicate post-surgery recovery, increasing the risk of infections and other complications, which may prolong hospital stays and lead to a higher likelihood of adverse outcomes. Overall limiting the appendicitis market.